News & Updates
Filter by Specialty:
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
03 Feb 2023COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK
According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong.
COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK
02 Feb 2023Study supports safety of fourth BNT162b2 mRNA vaccine
A study from Israel validated the safety of the fourth BNT162b2 mRNA COVID-19 vaccine (ie, second booster) using data from a retrospective and a prospective cohort.
Study supports safety of fourth BNT162b2 mRNA vaccine
01 Feb 2023BNT162b2 vax prevents delta, omicron infection in adolescents; benefits upped with booster dose
Full vaccination with the SARS-CoV-2 BNT162b2 vaccine reduced infection and hospitalization due to the delta and omicron variants of the SARS-CoV-2 infection, with an added benefit against the omicron variant in individuals who received a booster dose, according to a national study of Singaporean adolescents.
BNT162b2 vax prevents delta, omicron infection in adolescents; benefits upped with booster dose
30 Jan 2023Long COVID may persist for months, resolve within a year
Patients with mild COVID-19 may encounter a few health concerns for several months following SARS-CoV-2 infection, but these outcomes tend to resolve within a year from diagnosis, reveals a study.
Long COVID may persist for months, resolve within a year
30 Jan 2023SAVE-MORE subgroup analysis further reinforces anakinra benefit in COVID-19
The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.